Sign In
Buy FULC
$3.58
-0.140 (-3.76%)
At Close: Jul 31, 2026
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) or certain of its executive officers violated federal securities la
FULC INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Fulcrum Therapeutics, Inc.
11:37am, Tuesday, 02'nd Jun 2026
ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC) complied with federal securities
Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns
06:39am, Tuesday, 02'nd Jun 2026
Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk con
FULC Stock Crashes After Hours: What Investors Need To Know
01:50am, Tuesday, 02'nd Jun 2026
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
05:10pm, Monday, 01'st Jun 2026
Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which left no viab
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
04:05pm, Monday, 01'st Jun 2026
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk p
After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)
10:35am, Wednesday, 20'th May 2026
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 08'th May 2026
CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of
Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript
11:21am, Monday, 27'th Apr 2026
Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
07:00am, Monday, 27'th Apr 2026
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occ
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
06:55am, Monday, 27'th Apr 2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improv
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules t
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Brokerages
04:08am, Saturday, 04'th Apr 2026
Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat reports. Two i
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis Three-year collaboration is aimed at enhancing a key aspect of sickle cell m
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Analysts
04:33am, Tuesday, 10'th Mar 2026
Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten research firms that are covering the stock, MarketBeat Rating
